Jiangsu Recbio Technology Co Ltd Sustainability Reports
The company is an innovative vaccine enterprise primarily engaged in the research, development, and commercialization of high-value recombinant protein, HPV, and shingles vaccine candidates.
Sector: Manufacturing
Country: China
Exchange: Hong Kong Stock Exchange
LEI: 254900UBG3389KI4UR87
FIGI: BBG0167SQCH3
9 reports from 2021 to 2025
- Jiangsu Recbio Technology Co Ltd 2025 Annual Report
- Jiangsu Recbio Technology Co Ltd 2024 Environmental, Social and Governance Report
- Jiangsu Recbio Technology Co Ltd 2024 Annual Report
- Jiangsu Recbio Technology Co Ltd 2023 Annual Report
- Jiangsu Recbio Technology Co Ltd 2023 Environmental, Social and Governance Report